uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q16.1239 | Q16 | What Small molecule therapies have been approved by the FDA to treat laryngeal carcinoma? | There are no drug Small molecule therapies approved to treat laryngeal carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "laryngeal carcinoma" OR LOWER(mesh_heading) = "laryngeal carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.364 | Q16 | What Small molecule therapies have been approved by the FDA to treat Birt-Hogg-Dube syndrome? | There are no drug Small molecule therapies approved to treat Birt-Hogg-Dube syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "birt-hogg-dube syndrome" OR LOWER(mesh_heading) = "birt-hogg-dube syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.611 | Q16 | What Small molecule therapies have been approved by the FDA to treat Renal Colic? | There are no drug Small molecule therapies approved to treat Renal Colic. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "renal colic" OR LOWER(mesh_heading) = "renal colic") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.552 | Q16 | What Small molecule therapies have been approved by the FDA to treat Multiple Organ Failure? | There are no drug Small molecule therapies approved to treat Multiple Organ Failure. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "multiple organ failure" OR LOWER(mesh_heading) = "multiple organ failure") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1183 | Q16 | What Small molecule therapies have been approved by the FDA to treat idiopathic pulmonary arterial hypertension? | Selexipag is the only Small molecule therapy approved by the FDA to treat idiopathic pulmonary arterial hypertension. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "idiopathic pulmonary arterial hypertension" OR LOWER(mesh_heading) = "idiopathic pulmonary arterial hypertension") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_246126', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246130', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246134', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246138', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246142', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246146', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246150', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246154', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246158', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246162', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246166', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246170', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246174', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246178', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246182', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246186', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246190', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246194', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246198', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246202', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246206', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246210', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246214', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246218', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246222', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246226', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246230', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246234', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246238', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246242', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246246', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246250', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246254', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246258', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246262', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246266', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246270', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246274', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246278', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246282', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246286', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246290', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246294', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246298', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246302', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246306', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246310', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246314', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246318', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246322', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246326', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246330', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.632 | Q16 | What Small molecule therapies have been approved by the FDA to treat Spinal cord injury? | There are 3 Small molecule therapy drugs that are approved to treat Spinal cord injury which are as follows: Pregabalin, Dantrolene Sodium, and Baclofen. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "spinal cord injury" OR LOWER(mesh_heading) = "spinal cord injury") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_859330', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_859382', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_859434', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_859486', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_859538', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_859590', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_859642', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_859694', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_859746', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_859798', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_859850', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_859902', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_859954', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_860006', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_860058', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_860110', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_860162', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_860214', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_860266', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_860318', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_860370', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_860422', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_860474', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_860526', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_860578', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_860630', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_860682', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_860734', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_860786', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_860838', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_860890', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_860942', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_860994', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_861046', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_861098', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_861150', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_861202', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_861254', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_861306', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_861358', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_861410', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_861462', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_861514', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_861566', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_861618', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_861670', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_861722', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_861774', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_861826', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_861878', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_861930', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_861982', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_862034', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_862086', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_862138', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_862190', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_862242', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_862294', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_862346', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_862398', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_862450', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_862502', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_862554', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_862606', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_862658', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_862710', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_862762', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_862814', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_862866', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_862918', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_862970', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_863022', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_863074', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_863126', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_863178', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_863230', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_863282', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_863334', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_863386', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_863438', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_863490', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_863542', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_863594', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_863646', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_863698', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_863750', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_863802', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_863854', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_863906', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_863958', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_864010', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_864062', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_864114', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_864166', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_864218', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_864270', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_864322', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_864374', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_864426', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}, {'UUID': 'DrugTargetsIndication121923_text_864478', 'drugName': 'Pregabalin', 'tradeNames_list': "['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Rewisca']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Injuries', 'efo_term': 'Spinal cord injury'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1446 | Q16 | What Small molecule therapies have been approved by the FDA to treat papilloma? | There are no drug Small molecule therapies approved to treat papilloma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "papilloma" OR LOWER(mesh_heading) = "papilloma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1335 | Q16 | What Small molecule therapies have been approved by the FDA to treat mucinous carcinoma? | There are no drug Small molecule therapies approved to treat mucinous carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "mucinous carcinoma" OR LOWER(mesh_heading) = "mucinous carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1419 | Q16 | What Small molecule therapies have been approved by the FDA to treat osteoarthritis, knee? | There are no drug Small molecule therapies approved to treat osteoarthritis, knee. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "osteoarthritis, knee" OR LOWER(mesh_heading) = "osteoarthritis, knee") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1517 | Q16 | What Small molecule therapies have been approved by the FDA to treat premature birth? | Hydroxyprogesterone Caproate is the only Small molecule therapy approved by the FDA to treat premature birth. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "premature birth" OR LOWER(mesh_heading) = "premature birth") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_940452', 'drugName': 'Hydroxyprogesterone Caproate', 'tradeNames_list': "['Delalutin', 'Hydroxyprogesterone caproate', 'MakenaMakena (autoinjector)', 'Makena preservative free', 'Proluton depot']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Premature Birth', 'efo_term': 'premature birth'}, {'UUID': 'DrugTargetsIndication121923_text_940454', 'drugName': 'Hydroxyprogesterone Caproate', 'tradeNames_list': "['Delalutin', 'Hydroxyprogesterone caproate', 'MakenaMakena (autoinjector)', 'Makena preservative free', 'Proluton depot']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Premature Birth', 'efo_term': 'premature birth'}, {'UUID': 'DrugTargetsIndication121923_text_940456', 'drugName': 'Hydroxyprogesterone Caproate', 'tradeNames_list': "['Delalutin', 'Hydroxyprogesterone caproate', 'MakenaMakena (autoinjector)', 'Makena preservative free', 'Proluton depot']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Premature Birth', 'efo_term': 'premature birth'}, {'UUID': 'DrugTargetsIndication121923_text_940458', 'drugName': 'Hydroxyprogesterone Caproate', 'tradeNames_list': "['Delalutin', 'Hydroxyprogesterone caproate', 'MakenaMakena (autoinjector)', 'Makena preservative free', 'Proluton depot']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Premature Birth', 'efo_term': 'premature birth'}, {'UUID': 'DrugTargetsIndication121923_text_940460', 'drugName': 'Hydroxyprogesterone Caproate', 'tradeNames_list': "['Delalutin', 'Hydroxyprogesterone caproate', 'MakenaMakena (autoinjector)', 'Makena preservative free', 'Proluton depot']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Premature Birth', 'efo_term': 'premature birth'}, {'UUID': 'DrugTargetsIndication121923_text_940462', 'drugName': 'Hydroxyprogesterone Caproate', 'tradeNames_list': "['Delalutin', 'Hydroxyprogesterone caproate', 'MakenaMakena (autoinjector)', 'Makena preservative free', 'Proluton depot']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Premature Birth', 'efo_term': 'premature birth'}, {'UUID': 'DrugTargetsIndication121923_text_940464', 'drugName': 'Hydroxyprogesterone Caproate', 'tradeNames_list': "['Delalutin', 'Hydroxyprogesterone caproate', 'MakenaMakena (autoinjector)', 'Makena preservative free', 'Proluton depot']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Premature Birth', 'efo_term': 'premature birth'}, {'UUID': 'DrugTargetsIndication121923_text_940466', 'drugName': 'Hydroxyprogesterone Caproate', 'tradeNames_list': "['Delalutin', 'Hydroxyprogesterone caproate', 'MakenaMakena (autoinjector)', 'Makena preservative free', 'Proluton depot']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Premature Birth', 'efo_term': 'premature birth'}, {'UUID': 'DrugTargetsIndication121923_text_940468', 'drugName': 'Hydroxyprogesterone Caproate', 'tradeNames_list': "['Delalutin', 'Hydroxyprogesterone caproate', 'MakenaMakena (autoinjector)', 'Makena preservative free', 'Proluton depot']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Premature Birth', 'efo_term': 'premature birth'}, {'UUID': 'DrugTargetsIndication121923_text_940470', 'drugName': 'Hydroxyprogesterone Caproate', 'tradeNames_list': "['Delalutin', 'Hydroxyprogesterone caproate', 'MakenaMakena (autoinjector)', 'Makena preservative free', 'Proluton depot']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Premature Birth', 'efo_term': 'premature birth'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1341 | Q16 | What Small molecule therapies have been approved by the FDA to treat multiple system atrophy? | There are no drug Small molecule therapies approved to treat multiple system atrophy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "multiple system atrophy" OR LOWER(mesh_heading) = "multiple system atrophy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1723 | Q16 | What Small molecule therapies have been approved by the FDA to treat upper aerodigestive tract neoplasm? | There are no drug Small molecule therapies approved to treat upper aerodigestive tract neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "upper aerodigestive tract neoplasm" OR LOWER(mesh_heading) = "upper aerodigestive tract neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.673 | Q16 | What Small molecule therapies have been approved by the FDA to treat Uterine Carcinosarcoma? | There are no drug Small molecule therapies approved to treat Uterine Carcinosarcoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "uterine carcinosarcoma" OR LOWER(mesh_heading) = "uterine carcinosarcoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.721 | Q16 | What Small molecule therapies have been approved by the FDA to treat adrenocortical insufficiency? | There are no drug Small molecule therapies approved to treat adrenocortical insufficiency. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "adrenocortical insufficiency" OR LOWER(mesh_heading) = "adrenocortical insufficiency") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1257 | Q16 | What Small molecule therapies have been approved by the FDA to treat liver disease? | Avatrombopag Maleate is the only Small molecule therapy approved by the FDA to treat liver disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "liver disease" OR LOWER(mesh_heading) = "liver disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1055939', 'drugName': 'Avatrombopag Maleate', 'tradeNames_list': "['Doptelet']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Diseases', 'efo_term': 'liver disease'}, {'UUID': 'DrugTargetsIndication121923_text_1055941', 'drugName': 'Avatrombopag Maleate', 'tradeNames_list': "['Doptelet']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Diseases', 'efo_term': 'liver disease'}, {'UUID': 'DrugTargetsIndication121923_text_1055943', 'drugName': 'Avatrombopag Maleate', 'tradeNames_list': "['Doptelet']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Diseases', 'efo_term': 'liver disease'}, {'UUID': 'DrugTargetsIndication121923_text_1055945', 'drugName': 'Avatrombopag Maleate', 'tradeNames_list': "['Doptelet']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Diseases', 'efo_term': 'liver disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1479 | Q16 | What Small molecule therapies have been approved by the FDA to treat pilocytic astrocytoma? | There are no drug Small molecule therapies approved to treat pilocytic astrocytoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pilocytic astrocytoma" OR LOWER(mesh_heading) = "pilocytic astrocytoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1704 | Q16 | What Small molecule therapies have been approved by the FDA to treat toxic epidermal necrolysis? | There are no drug Small molecule therapies approved to treat toxic epidermal necrolysis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "toxic epidermal necrolysis" OR LOWER(mesh_heading) = "toxic epidermal necrolysis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1470 | Q16 | What Small molecule therapies have been approved by the FDA to treat persian gulf syndrome? | There are no drug Small molecule therapies approved to treat persian gulf syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "persian gulf syndrome" OR LOWER(mesh_heading) = "persian gulf syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.606 | Q16 | What Small molecule therapies have been approved by the FDA to treat Radiation Pneumonitis? | There are no drug Small molecule therapies approved to treat Radiation Pneumonitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "radiation pneumonitis" OR LOWER(mesh_heading) = "radiation pneumonitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.901 | Q16 | What Small molecule therapies have been approved by the FDA to treat cholesterol embolism? | There are no drug Small molecule therapies approved to treat cholesterol embolism. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cholesterol embolism" OR LOWER(mesh_heading) = "cholesterol embolism") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1488 | Q16 | What Small molecule therapies have been approved by the FDA to treat pneumocystosis? | There are no drug Small molecule therapies approved to treat pneumocystosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pneumocystosis" OR LOWER(mesh_heading) = "pneumocystosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1001 | Q16 | What Small molecule therapies have been approved by the FDA to treat discoid lupus erythematosus? | There are no drug Small molecule therapies approved to treat discoid lupus erythematosus. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "discoid lupus erythematosus" OR LOWER(mesh_heading) = "discoid lupus erythematosus") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.849 | Q16 | What Small molecule therapies have been approved by the FDA to treat bronchiolitis obliterans? | There are no drug Small molecule therapies approved to treat bronchiolitis obliterans. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bronchiolitis obliterans" OR LOWER(mesh_heading) = "bronchiolitis obliterans") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.658 | Q16 | What Small molecule therapies have been approved by the FDA to treat Thymic Carcinoma? | There are no drug Small molecule therapies approved to treat Thymic Carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "thymic carcinoma" OR LOWER(mesh_heading) = "thymic carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1752 | Q16 | What Small molecule therapies have been approved by the FDA to treat vestibular neuronitis? | There are no drug Small molecule therapies approved to treat vestibular neuronitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "vestibular neuronitis" OR LOWER(mesh_heading) = "vestibular neuronitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1037 | Q16 | What Small molecule therapies have been approved by the FDA to treat erectile dysfunction? | There are 4 Small molecule therapy drugs that are approved to treat erectile dysfunction which are as follows: Avanafil, Tadalafil, Vardenafil Hydrochloride, and Vardenafil. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "erectile dysfunction" OR LOWER(mesh_heading) = "erectile dysfunction") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094059', 'drugName': 'Avanafil', 'tradeNames_list': "['Spedra', 'Stendra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094061', 'drugName': 'Avanafil', 'tradeNames_list': "['Spedra', 'Stendra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094063', 'drugName': 'Avanafil', 'tradeNames_list': "['Spedra', 'Stendra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094065', 'drugName': 'Avanafil', 'tradeNames_list': "['Spedra', 'Stendra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094067', 'drugName': 'Avanafil', 'tradeNames_list': "['Spedra', 'Stendra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094069', 'drugName': 'Avanafil', 'tradeNames_list': "['Spedra', 'Stendra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094099', 'drugName': 'Tadalafil', 'tradeNames_list': "['Adcirca', 'Cialis', 'Tadliq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'Impotence'}, {'UUID': 'DrugTargetsIndication121923_text_1094103', 'drugName': 'Tadalafil', 'tradeNames_list': "['Adcirca', 'Cialis', 'Tadliq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094107', 'drugName': 'Vardenafil Hydrochloride', 'tradeNames_list': "['Levitra', 'Staxyn', 'Vardenafil hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094108', 'drugName': 'Vardenafil Hydrochloride', 'tradeNames_list': "['Levitra', 'Staxyn', 'Vardenafil hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094109', 'drugName': 'Vardenafil Hydrochloride', 'tradeNames_list': "['Levitra', 'Staxyn', 'Vardenafil hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094110', 'drugName': 'Vardenafil Hydrochloride', 'tradeNames_list': "['Levitra', 'Staxyn', 'Vardenafil hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094111', 'drugName': 'Vardenafil Hydrochloride', 'tradeNames_list': "['Levitra', 'Staxyn', 'Vardenafil hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094112', 'drugName': 'Vardenafil Hydrochloride', 'tradeNames_list': "['Levitra', 'Staxyn', 'Vardenafil hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094113', 'drugName': 'Vardenafil Hydrochloride', 'tradeNames_list': "['Levitra', 'Staxyn', 'Vardenafil hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094114', 'drugName': 'Vardenafil Hydrochloride', 'tradeNames_list': "['Levitra', 'Staxyn', 'Vardenafil hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094115', 'drugName': 'Vardenafil Hydrochloride', 'tradeNames_list': "['Levitra', 'Staxyn', 'Vardenafil hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094123', 'drugName': 'Vardenafil', 'tradeNames_list': "['Levitra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094131', 'drugName': 'Vardenafil', 'tradeNames_list': "['Levitra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094139', 'drugName': 'Vardenafil', 'tradeNames_list': "['Levitra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094147', 'drugName': 'Vardenafil', 'tradeNames_list': "['Levitra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094155', 'drugName': 'Vardenafil', 'tradeNames_list': "['Levitra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094163', 'drugName': 'Vardenafil', 'tradeNames_list': "['Levitra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094171', 'drugName': 'Vardenafil', 'tradeNames_list': "['Levitra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094179', 'drugName': 'Vardenafil', 'tradeNames_list': "['Levitra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138735', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1294 | Q16 | What Small molecule therapies have been approved by the FDA to treat marginal zone B-cell lymphoma? | Umbralisib Tosylate is the only Small molecule therapy approved by the FDA to treat marginal zone B-cell lymphoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "marginal zone b-cell lymphoma" OR LOWER(mesh_heading) = "marginal zone b-cell lymphoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_744621', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744636', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744651', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744666', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744681', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744696', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744711', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744726', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744741', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744756', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744771', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744786', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744801', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744816', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744831', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744846', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744861', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744876', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744891', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744906', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744921', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744936', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744951', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744966', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744981', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_744996', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745011', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745026', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745041', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745056', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745071', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745086', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745101', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745116', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745131', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745146', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745161', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745176', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745191', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745206', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745221', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745236', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745251', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745266', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_745281', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1642 | Q16 | What Small molecule therapies have been approved by the FDA to treat spinal cord cancer? | There are no drug Small molecule therapies approved to treat spinal cord cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "spinal cord cancer" OR LOWER(mesh_heading) = "spinal cord cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.279 | Q16 | What Protein therapies have been approved by the FDA to treat pulmonary hypertension? | There are no drug Protein therapies approved to treat pulmonary hypertension. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pulmonary hypertension" OR LOWER(mesh_heading) = "pulmonary hypertension") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1361 | Q16 | What Small molecule therapies have been approved by the FDA to treat nasopharyngeal neoplasm? | There are no drug Small molecule therapies approved to treat nasopharyngeal neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "nasopharyngeal neoplasm" OR LOWER(mesh_heading) = "nasopharyngeal neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1624 | Q16 | What Small molecule therapies have been approved by the FDA to treat sickle cell anemia? | Voxelotor is the only Small molecule therapy approved by the FDA to treat sickle cell anemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "sickle cell anemia" OR LOWER(mesh_heading) = "sickle cell anemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1095584', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000206172', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095589', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000206172', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095594', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000206172', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095599', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000206172', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095604', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000206172', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095609', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000206172', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095614', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000206172', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095619', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000206172', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095624', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000206172', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095629', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000206172', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095634', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000206172', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095639', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000206172', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095644', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000206172', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095649', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000206172', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095654', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000206172', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095659', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000206172', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095664', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000206172', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095669', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000206172', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095674', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000206172', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095679', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000206172', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095684', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000206172', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095689', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000188536', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095694', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000188536', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095699', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000188536', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095704', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000188536', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095709', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000188536', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095714', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000188536', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095719', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000188536', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095724', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000188536', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095729', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000188536', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095734', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000188536', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095739', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000188536', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095744', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000188536', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095749', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000188536', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095754', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000188536', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095759', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000188536', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095764', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000188536', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095769', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000188536', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095774', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000188536', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095779', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000188536', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095784', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000188536', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095789', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000188536', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095794', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000244734', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095799', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000244734', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095804', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000244734', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095809', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000244734', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095814', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000244734', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095819', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000244734', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095824', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000244734', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095829', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000244734', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095834', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000244734', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095839', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000244734', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095844', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000244734', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095849', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000244734', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095854', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000244734', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095859', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000244734', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095864', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000244734', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095869', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000244734', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095874', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000244734', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095879', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000244734', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095884', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000244734', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095889', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000244734', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1095894', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000244734', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.361 | Q16 | What Small molecule therapies have been approved by the FDA to treat Benign essential blepharospasm? | There are no drug Small molecule therapies approved to treat Benign essential blepharospasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "benign essential blepharospasm" OR LOWER(mesh_heading) = "benign essential blepharospasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.950 | Q16 | What Small molecule therapies have been approved by the FDA to treat concussion? | There are no drug Small molecule therapies approved to treat concussion. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "concussion" OR LOWER(mesh_heading) = "concussion") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.238 | Q16 | What Protein therapies have been approved by the FDA to treat neurogenic arthropathy? | There are no drug Protein therapies approved to treat neurogenic arthropathy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "neurogenic arthropathy" OR LOWER(mesh_heading) = "neurogenic arthropathy") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.970 | Q16 | What Small molecule therapies have been approved by the FDA to treat cysticercosis? | There are no drug Small molecule therapies approved to treat cysticercosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cysticercosis" OR LOWER(mesh_heading) = "cysticercosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.807 | Q16 | What Small molecule therapies have been approved by the FDA to treat azoospermia? | There are no drug Small molecule therapies approved to treat azoospermia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "azoospermia" OR LOWER(mesh_heading) = "azoospermia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1687 | Q16 | What Small molecule therapies have been approved by the FDA to treat testicular carcinoma? | There are no drug Small molecule therapies approved to treat testicular carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "testicular carcinoma" OR LOWER(mesh_heading) = "testicular carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1698 | Q16 | What Small molecule therapies have been approved by the FDA to treat tibial muscular dystrophy? | There are no drug Small molecule therapies approved to treat tibial muscular dystrophy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "tibial muscular dystrophy" OR LOWER(mesh_heading) = "tibial muscular dystrophy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.489 | Q16 | What Small molecule therapies have been approved by the FDA to treat Herpes simplex infection? | There are no drug Small molecule therapies approved to treat Herpes simplex infection. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "herpes simplex infection" OR LOWER(mesh_heading) = "herpes simplex infection") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1215 | Q16 | What Small molecule therapies have been approved by the FDA to treat intracranial subdural hematoma? | There are no drug Small molecule therapies approved to treat intracranial subdural hematoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "intracranial subdural hematoma" OR LOWER(mesh_heading) = "intracranial subdural hematoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1303 | Q16 | What Small molecule therapies have been approved by the FDA to treat memory impairment? | There are no drug Small molecule therapies approved to treat memory impairment. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "memory impairment" OR LOWER(mesh_heading) = "memory impairment") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.209 | Q16 | What Protein therapies have been approved by the FDA to treat major depressive disorder? | There are no drug Protein therapies approved to treat major depressive disorder. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "major depressive disorder" OR LOWER(mesh_heading) = "major depressive disorder") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1582 | Q16 | What Small molecule therapies have been approved by the FDA to treat retinitis pigmentosa? | There are no drug Small molecule therapies approved to treat retinitis pigmentosa. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "retinitis pigmentosa" OR LOWER(mesh_heading) = "retinitis pigmentosa") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1375 | Q16 | What Small molecule therapies have been approved by the FDA to treat neurofibromatosis? | Selumetinib Sulfate is the only Small molecule therapy approved by the FDA to treat neurofibromatosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "neurofibromatosis" OR LOWER(mesh_heading) = "neurofibromatosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_932806', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis'}, {'UUID': 'DrugTargetsIndication121923_text_932812', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis'}, {'UUID': 'DrugTargetsIndication121923_text_932818', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis'}, {'UUID': 'DrugTargetsIndication121923_text_932824', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis'}, {'UUID': 'DrugTargetsIndication121923_text_932830', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis'}, {'UUID': 'DrugTargetsIndication121923_text_932836', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis'}, {'UUID': 'DrugTargetsIndication121923_text_932842', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis'}, {'UUID': 'DrugTargetsIndication121923_text_932848', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis'}, {'UUID': 'DrugTargetsIndication121923_text_932854', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis'}, {'UUID': 'DrugTargetsIndication121923_text_932860', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis'}, {'UUID': 'DrugTargetsIndication121923_text_932866', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis'}, {'UUID': 'DrugTargetsIndication121923_text_932872', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis'}, {'UUID': 'DrugTargetsIndication121923_text_932878', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis'}, {'UUID': 'DrugTargetsIndication121923_text_932884', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis'}, {'UUID': 'DrugTargetsIndication121923_text_932890', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis'}, {'UUID': 'DrugTargetsIndication121923_text_932896', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatoses', 'efo_term': 'neurofibromatosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1031 | Q16 | What Small molecule therapies have been approved by the FDA to treat epicondylitis? | Triamcinolone Acetonide is the only Small molecule therapy approved by the FDA to treat epicondylitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "epicondylitis" OR LOWER(mesh_heading) = "epicondylitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_221884', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_221949', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_222014', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_222079', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_222144', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_222209', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_222274', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_222339', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'epicondylitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.59 | Q16 | What Protein therapies have been approved by the FDA to treat Pruritus? | Difelikefalin is the only Protein therapy approved by the FDA to treat Pruritus. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pruritus" OR LOWER(mesh_heading) = "pruritus") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1092252', 'drugName': 'Difelikefalin', 'tradeNames_list': "['Korsuva']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus'}, {'UUID': 'DrugTargetsIndication121923_text_1092256', 'drugName': 'Difelikefalin', 'tradeNames_list': "['Korsuva']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus'}, {'UUID': 'DrugTargetsIndication121923_text_1092260', 'drugName': 'Difelikefalin', 'tradeNames_list': "['Korsuva']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus'}, {'UUID': 'DrugTargetsIndication121923_text_1092264', 'drugName': 'Difelikefalin', 'tradeNames_list': "['Korsuva']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus'}, {'UUID': 'DrugTargetsIndication121923_text_1092268', 'drugName': 'Difelikefalin', 'tradeNames_list': "['Korsuva']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus'}, {'UUID': 'DrugTargetsIndication121923_text_1092272', 'drugName': 'Difelikefalin', 'tradeNames_list': "['Korsuva']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus'}, {'UUID': 'DrugTargetsIndication121923_text_1092276', 'drugName': 'Difelikefalin', 'tradeNames_list': "['Korsuva']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus'}, {'UUID': 'DrugTargetsIndication121923_text_1092280', 'drugName': 'Difelikefalin', 'tradeNames_list': "['Korsuva']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus'}, {'UUID': 'DrugTargetsIndication121923_text_1092284', 'drugName': 'Difelikefalin', 'tradeNames_list': "['Korsuva']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus'}, {'UUID': 'DrugTargetsIndication121923_text_1092288', 'drugName': 'Difelikefalin', 'tradeNames_list': "['Korsuva']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus'}, {'UUID': 'DrugTargetsIndication121923_text_1092292', 'drugName': 'Difelikefalin', 'tradeNames_list': "['Korsuva']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus'}, {'UUID': 'DrugTargetsIndication121923_text_1092296', 'drugName': 'Difelikefalin', 'tradeNames_list': "['Korsuva']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.600 | Q16 | What Small molecule therapies have been approved by the FDA to treat Priapism? | There are no drug Small molecule therapies approved to treat Priapism. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "priapism" OR LOWER(mesh_heading) = "priapism") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1398 | Q16 | What Small molecule therapies have been approved by the FDA to treat oligodendroglioma? | There are no drug Small molecule therapies approved to treat oligodendroglioma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "oligodendroglioma" OR LOWER(mesh_heading) = "oligodendroglioma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.614 | Q16 | What Small molecule therapies have been approved by the FDA to treat Respiratory insufficiency? | Nitric Oxide is the only Small molecule therapy approved by the FDA to treat Respiratory insufficiency. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "respiratory insufficiency" OR LOWER(mesh_heading) = "respiratory insufficiency") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_974151', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_974154', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974205', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_974208', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974259', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_974262', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974313', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_974316', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974367', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_974370', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974421', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_974424', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974475', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_974478', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974529', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_974532', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974583', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_974586', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974637', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_974640', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974691', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_974694', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974745', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_974748', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974799', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_974802', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974853', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_974856', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974907', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_974910', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_974961', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_974964', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975015', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_975018', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975069', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_975072', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975123', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_975126', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975177', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_975180', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975231', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_975234', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975285', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_975288', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975339', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_975342', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975393', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_975396', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975447', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_975450', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975501', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_975504', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975555', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_975558', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975609', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_975612', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975663', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_975666', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975717', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_975720', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975771', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_975774', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975825', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_975828', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975879', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_975882', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975933', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_975936', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_975987', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_975990', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976041', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_976044', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976095', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_976098', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976149', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_976152', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976203', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_976206', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976257', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_976260', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976311', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_976314', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976365', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_976368', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976419', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_976422', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976473', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_976476', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976527', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_976530', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976581', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_976584', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976635', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_976638', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976689', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_976692', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976743', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_976746', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}, {'UUID': 'DrugTargetsIndication121923_text_976797', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_976800', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1201 | Q16 | What Small molecule therapies have been approved by the FDA to treat intellectual disability? | There are no drug Small molecule therapies approved to treat intellectual disability. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "intellectual disability" OR LOWER(mesh_heading) = "intellectual disability") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1392 | Q16 | What Small molecule therapies have been approved by the FDA to treat obesity? | There are 2 Small molecule therapy drugs that are approved to treat obesity which are as follows: Dextroamphetamine and Phentermine Hydrochloride. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "obesity" OR LOWER(mesh_heading) = "obesity") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_418358', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418371', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418384', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418397', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418410', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418423', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418436', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418449', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418462', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418475', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418488', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418501', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418514', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418527', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418540', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418553', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418566', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418579', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418592', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418605', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418618', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418631', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418644', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418657', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418670', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418683', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418696', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418709', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418722', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418735', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418748', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418761', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418774', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418787', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418800', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418813', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418826', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418839', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418852', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418865', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418878', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418891', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418904', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418917', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418930', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418943', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418956', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418969', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418982', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_418995', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_419008', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_419021', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_419034', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_419047', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_419060', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_419073', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_419086', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_419099', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_419112', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_419125', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_434240', 'drugName': 'Phentermine Hydrochloride', 'tradeNames_list': "['Adipex-p', 'Fastin', 'Lomaira', 'Obestin-30', 'Oby-trim', 'Ona-mastPhentermine hydrochloride', 'Suprenza', 'Tora', 'Wilpo']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1973, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_434241', 'drugName': 'Phentermine Hydrochloride', 'tradeNames_list': "['Adipex-p', 'Fastin', 'Lomaira', 'Obestin-30', 'Oby-trim', 'Ona-mastPhentermine hydrochloride', 'Suprenza', 'Tora', 'Wilpo']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1973, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}, {'UUID': 'DrugTargetsIndication121923_text_434242', 'drugName': 'Phentermine Hydrochloride', 'tradeNames_list': "['Adipex-p', 'Fastin', 'Lomaira', 'Obestin-30', 'Oby-trim', 'Ona-mastPhentermine hydrochloride', 'Suprenza', 'Tora', 'Wilpo']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1973, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.366 | Q16 | What Small molecule therapies have been approved by the FDA to treat Blindness? | There are no drug Small molecule therapies approved to treat Blindness. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "blindness" OR LOWER(mesh_heading) = "blindness") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.827 | Q16 | What Small molecule therapies have been approved by the FDA to treat blepharitis? | There are no drug Small molecule therapies approved to treat blepharitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "blepharitis" OR LOWER(mesh_heading) = "blepharitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.357 | Q16 | What Small molecule therapies have been approved by the FDA to treat Back pain? | There are 8 Small molecule therapy drugs that are approved to treat Back pain which are as follows: Lidocaine Hydrochloride, Lidocaine, Acetaminophen, Aspirin, Naproxen Sodium, Naproxen, Ibuprofen, and Capsaicin. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "back pain" OR LOWER(mesh_heading) = "back pain") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_636907', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_636927', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_636947', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_636967', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_636987', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637007', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637027', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637047', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637067', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637087', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637107', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637127', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637147', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637167', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637187', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637207', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637227', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637247', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637267', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637287', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637307', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637327', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637347', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637367', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637387', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637407', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637427', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637447', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637467', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637487', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637507', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637527', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637547', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637567', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637587', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637607', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637627', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637647', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637667', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637687', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637778', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_637893', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_638008', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_638123', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_638238', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_638353', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_638468', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_638583', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_638698', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_638813', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_638928', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_639043', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_639158', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_639273', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_639388', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_639503', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_639618', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_639733', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_639848', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_639963', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_640078', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_640193', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_640308', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_640423', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_640538', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_640653', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_640768', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_640883', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_640998', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_641113', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_641228', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_641343', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_641458', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_641573', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_641688', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_641803', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_641918', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_642033', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_642148', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_642263', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_642378', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_642493', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_642608', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_642723', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_642838', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_642953', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_643068', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_643183', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_643298', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_643413', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_643528', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_643643', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_643758', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_643873', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_643988', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_644103', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_644218', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_644333', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_644448', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}, {'UUID': 'DrugTargetsIndication121923_text_644563', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.431 | Q16 | What Small molecule therapies have been approved by the FDA to treat Esophageal stricture? | There are no drug Small molecule therapies approved to treat Esophageal stricture. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "esophageal stricture" OR LOWER(mesh_heading) = "esophageal stricture") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.971 | Q16 | What Small molecule therapies have been approved by the FDA to treat cystoid macular edema? | Dexamethasone is the only Small molecule therapy approved by the FDA to treat cystoid macular edema. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cystoid macular edema" OR LOWER(mesh_heading) = "cystoid macular edema") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_226381', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema'}, {'UUID': 'DrugTargetsIndication121923_text_226666', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema'}, {'UUID': 'DrugTargetsIndication121923_text_226951', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema'}, {'UUID': 'DrugTargetsIndication121923_text_227236', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema'}, {'UUID': 'DrugTargetsIndication121923_text_227521', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema'}, {'UUID': 'DrugTargetsIndication121923_text_227806', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema'}, {'UUID': 'DrugTargetsIndication121923_text_228091', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema'}, {'UUID': 'DrugTargetsIndication121923_text_228376', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema'}, {'UUID': 'DrugTargetsIndication121923_text_228661', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema'}, {'UUID': 'DrugTargetsIndication121923_text_228946', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema'}, {'UUID': 'DrugTargetsIndication121923_text_229231', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema'}, {'UUID': 'DrugTargetsIndication121923_text_229516', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema'}, {'UUID': 'DrugTargetsIndication121923_text_229801', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema'}, {'UUID': 'DrugTargetsIndication121923_text_230086', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema'}, {'UUID': 'DrugTargetsIndication121923_text_230371', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema'}, {'UUID': 'DrugTargetsIndication121923_text_230656', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema'}, {'UUID': 'DrugTargetsIndication121923_text_230941', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema'}, {'UUID': 'DrugTargetsIndication121923_text_231226', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema'}, {'UUID': 'DrugTargetsIndication121923_text_231511', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema'}, {'UUID': 'DrugTargetsIndication121923_text_231796', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema'}, {'UUID': 'DrugTargetsIndication121923_text_232081', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema'}, {'UUID': 'DrugTargetsIndication121923_text_232366', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1414 | Q16 | What Small molecule therapies have been approved by the FDA to treat oropharynx squamous cell carcinoma? | There are no drug Small molecule therapies approved to treat oropharynx squamous cell carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "oropharynx squamous cell carcinoma" OR LOWER(mesh_heading) = "oropharynx squamous cell carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1600 | Q16 | What Small molecule therapies have been approved by the FDA to treat sarcopenia? | There are no drug Small molecule therapies approved to treat sarcopenia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "sarcopenia" OR LOWER(mesh_heading) = "sarcopenia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.558 | Q16 | What Small molecule therapies have been approved by the FDA to treat Myelopathy? | There are no drug Small molecule therapies approved to treat Myelopathy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "myelopathy" OR LOWER(mesh_heading) = "myelopathy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1268 | Q16 | What Small molecule therapies have been approved by the FDA to treat lymphedema? | There are no drug Small molecule therapies approved to treat lymphedema. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "lymphedema" OR LOWER(mesh_heading) = "lymphedema") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.711 | Q16 | What Small molecule therapies have been approved by the FDA to treat acute myocardial infarction? | There are 3 Small molecule therapy drugs that are approved to treat acute myocardial infarction which are as follows: Aspirin, Ticagrelor, and Simvastatin. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "acute myocardial infarction" OR LOWER(mesh_heading) = "acute myocardial infarction") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_833652', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_833809', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_833966', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_834123', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_834280', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_834437', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_834594', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_834751', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_834908', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_835065', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_835222', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_835379', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_835536', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_835693', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_835850', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_836007', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920339', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920365', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920391', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920417', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920443', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920469', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920495', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920521', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920547', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920573', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920599', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920625', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920651', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920677', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920703', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920729', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920755', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920781', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920807', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920833', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920859', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920885', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920911', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920937', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920963', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_920989', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_1103798', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_1103902', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_1104006', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}, {'UUID': 'DrugTargetsIndication121923_text_1104110', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113161', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.294 | Q16 | What Protein therapies have been approved by the FDA to treat sickle cell anemia? | There are no drug Protein therapies approved to treat sickle cell anemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "sickle cell anemia" OR LOWER(mesh_heading) = "sickle cell anemia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1406 | Q16 | What Small molecule therapies have been approved by the FDA to treat oral mucositis? | There are no drug Small molecule therapies approved to treat oral mucositis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "oral mucositis" OR LOWER(mesh_heading) = "oral mucositis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1349 | Q16 | What Small molecule therapies have been approved by the FDA to treat myelodysplastic/myeloproliferative disease? | There are no drug Small molecule therapies approved to treat myelodysplastic/myeloproliferative disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "myelodysplastic/myeloproliferative disease" OR LOWER(mesh_heading) = "myelodysplastic/myeloproliferative disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1608 | Q16 | What Small molecule therapies have been approved by the FDA to treat scrub typhus? | There are no drug Small molecule therapies approved to treat scrub typhus. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "scrub typhus" OR LOWER(mesh_heading) = "scrub typhus") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.119 | Q16 | What Protein therapies have been approved by the FDA to treat cardiac arrest? | There are no drug Protein therapies approved to treat cardiac arrest. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cardiac arrest" OR LOWER(mesh_heading) = "cardiac arrest") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1275 | Q16 | What Small molecule therapies have been approved by the FDA to treat lymphoplasmacytic lymphoma? | There are no drug Small molecule therapies approved to treat lymphoplasmacytic lymphoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "lymphoplasmacytic lymphoma" OR LOWER(mesh_heading) = "lymphoplasmacytic lymphoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.947 | Q16 | What Small molecule therapies have been approved by the FDA to treat common cold? | There are 8 Small molecule therapy drugs that are approved to treat common cold which are as follows: Phenylephrine Hydrochloride, Oxymetazoline Hydrochloride, Ephedrine Sulfate, Acetaminophen, Aspirin, Naproxen, Ibuprofen, and Ipratropium Bromide. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "common cold" OR LOWER(mesh_heading) = "common cold") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_416612', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_416630', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_416648', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_416666', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_416684', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_416702', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417192', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417202', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417212', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417222', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417232', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417242', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417252', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417262', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417272', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417282', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417292', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417302', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417312', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417322', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417332', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417342', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417352', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417362', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417372', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417382', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417392', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417402', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417412', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417422', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417432', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417442', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417452', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417462', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417472', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417482', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417492', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417502', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417512', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417522', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417532', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417542', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417552', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417562', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417572', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417582', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417592', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417602', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417612', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417622', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417632', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417642', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417652', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417662', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417672', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417682', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417692', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417702', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417712', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417722', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417732', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417742', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417752', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417762', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417772', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417782', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417792', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417802', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417812', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417822', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417832', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417842', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417852', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417862', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417872', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417882', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417892', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417902', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417912', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417922', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417932', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417942', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417952', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417962', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417972', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417982', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_417992', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_418002', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_418012', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_418022', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_418032', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_418042', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_418052', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_418062', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_418072', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_418082', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_418092', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_418102', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_418112', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}, {'UUID': 'DrugTargetsIndication121923_text_418122', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.633 | Q16 | What Small molecule therapies have been approved by the FDA to treat Stargardt disease? | There are no drug Small molecule therapies approved to treat Stargardt disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "stargardt disease" OR LOWER(mesh_heading) = "stargardt disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.517 | Q16 | What Small molecule therapies have been approved by the FDA to treat Intervertebral disc degeneration? | There are no drug Small molecule therapies approved to treat Intervertebral disc degeneration. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "intervertebral disc degeneration" OR LOWER(mesh_heading) = "intervertebral disc degeneration") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.82 | Q16 | What Protein therapies have been approved by the FDA to treat acute lymphoblastic leukemia? | There are no drug Protein therapies approved to treat acute lymphoblastic leukemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "acute lymphoblastic leukemia" OR LOWER(mesh_heading) = "acute lymphoblastic leukemia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1330 | Q16 | What Small molecule therapies have been approved by the FDA to treat mood disorder? | Bupropion Hydrochloride is the only Small molecule therapy approved by the FDA to treat mood disorder. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "mood disorder" OR LOWER(mesh_heading) = "mood disorder") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_434124', 'drugName': 'Bupropion Hydrochloride', 'tradeNames_list': "['Bupropion hydrochloride', 'Forfivo xl', 'Wellbutrin', 'Wellbutrin 100Wellbutrin 75', 'Wellbutrin sr', 'Wellbutrin xl', 'Zyban']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mood Disorders', 'efo_term': 'mood disorder'}, {'UUID': 'DrugTargetsIndication121923_text_434140', 'drugName': 'Bupropion Hydrochloride', 'tradeNames_list': "['Bupropion hydrochloride', 'Forfivo xl', 'Wellbutrin', 'Wellbutrin 100Wellbutrin 75', 'Wellbutrin sr', 'Wellbutrin xl', 'Zyban']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mood Disorders', 'efo_term': 'mood disorder'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.383 | Q16 | What Small molecule therapies have been approved by the FDA to treat Charcot-Marie-Tooth disease type 1A? | There are no drug Small molecule therapies approved to treat Charcot-Marie-Tooth disease type 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "charcot-marie-tooth disease type 1a" OR LOWER(mesh_heading) = "charcot-marie-tooth disease type 1a") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1688 | Q16 | What Small molecule therapies have been approved by the FDA to treat testicular neoplasm? | There are no drug Small molecule therapies approved to treat testicular neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "testicular neoplasm" OR LOWER(mesh_heading) = "testicular neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.85 | Q16 | What Protein therapies have been approved by the FDA to treat adenocarcinoma? | There are no drug Protein therapies approved to treat adenocarcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "adenocarcinoma" OR LOWER(mesh_heading) = "adenocarcinoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1481 | Q16 | What Small molecule therapies have been approved by the FDA to treat placenta accreta? | There are no drug Small molecule therapies approved to treat placenta accreta. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "placenta accreta" OR LOWER(mesh_heading) = "placenta accreta") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1250 | Q16 | What Small molecule therapies have been approved by the FDA to treat lethal midline granuloma? | There are no drug Small molecule therapies approved to treat lethal midline granuloma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "lethal midline granuloma" OR LOWER(mesh_heading) = "lethal midline granuloma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.882 | Q16 | What Small molecule therapies have been approved by the FDA to treat cerebral atherosclerosis? | Amantadine Hydrochloride is the only Small molecule therapy approved by the FDA to treat cerebral atherosclerosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cerebral atherosclerosis" OR LOWER(mesh_heading) = "cerebral atherosclerosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_441021', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441035', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441049', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441063', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441077', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441091', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441105', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441119', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441133', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441147', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441161', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441175', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441189', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441203', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441217', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441231', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441245', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441259', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441273', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441287', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441301', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441315', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441329', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441343', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441357', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441371', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441385', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441399', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441413', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441427', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441441', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441455', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441469', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441483', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441497', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441511', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441525', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441539', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441553', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441567', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441581', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441595', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441609', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441623', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441637', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441651', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441665', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441679', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441693', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441707', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441721', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441735', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441749', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441763', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441777', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441791', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441805', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441819', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441833', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441847', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441861', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441875', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441889', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441903', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441917', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441931', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441945', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441959', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441973', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_441987', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442001', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442015', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442029', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442043', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442057', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442071', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442085', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442099', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442113', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442127', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442141', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442155', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442169', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442183', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442197', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442211', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442225', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442239', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442253', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442267', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442281', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442295', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442309', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442323', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442337', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442351', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442365', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442379', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442393', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_442407', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.589 | Q16 | What Small molecule therapies have been approved by the FDA to treat Peutz-Jeghers syndrome? | There are no drug Small molecule therapies approved to treat Peutz-Jeghers syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "peutz-jeghers syndrome" OR LOWER(mesh_heading) = "peutz-jeghers syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1352 | Q16 | What Small molecule therapies have been approved by the FDA to treat myeloid sarcoma? | There are no drug Small molecule therapies approved to treat myeloid sarcoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "myeloid sarcoma" OR LOWER(mesh_heading) = "myeloid sarcoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.780 | Q16 | What Small molecule therapies have been approved by the FDA to treat anxiety disorder? | There are 4 Small molecule therapy drugs that are approved to treat anxiety disorder which are as follows: Duloxetine Hydrochloride, Escitalopram Oxalate, Lorazepam, and Diazepam. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "anxiety disorder" OR LOWER(mesh_heading) = "anxiety disorder") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205999', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206015', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206031', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206047', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206063', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206079', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206095', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206111', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206127', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206143', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206159', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206175', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206191', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206207', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206223', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206239', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206255', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206271', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206287', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206303', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206319', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206335', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206351', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206367', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206383', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206399', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206415', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206431', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206447', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206463', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206479', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206495', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206502', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206503', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206511', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206512', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206520', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206521', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206529', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206530', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206538', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206539', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206547', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206548', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206556', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206557', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206565', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206566', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206574', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206575', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206583', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206584', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206592', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206593', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206601', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_206602', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_958469', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_958496', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_958523', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_958550', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_958577', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_958604', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_958631', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_958658', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_958685', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_958712', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_958739', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_958766', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_958793', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_958820', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_958847', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_958874', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_958901', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_958928', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_958955', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_958982', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_959009', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_959036', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_959063', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_959090', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_959117', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000268089', 'approvedSymbol': 'GABRQ', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit theta', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_959144', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000268089', 'approvedSymbol': 'GABRQ', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit theta', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_959171', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000268089', 'approvedSymbol': 'GABRQ', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit theta', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_959198', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000268089', 'approvedSymbol': 'GABRQ', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit theta', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_959225', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000011677', 'approvedSymbol': 'GABRA3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha3', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_959252', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000011677', 'approvedSymbol': 'GABRA3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha3', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_959279', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000011677', 'approvedSymbol': 'GABRA3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha3', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_959306', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000011677', 'approvedSymbol': 'GABRA3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha3', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_959333', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000094755', 'approvedSymbol': 'GABRP', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit pi', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_959360', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000094755', 'approvedSymbol': 'GABRP', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit pi', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_959387', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000094755', 'approvedSymbol': 'GABRP', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit pi', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_959414', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000094755', 'approvedSymbol': 'GABRP', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit pi', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_959441', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000187730', 'approvedSymbol': 'GABRD', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit delta', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_959468', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000187730', 'approvedSymbol': 'GABRD', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit delta', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_959495', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000187730', 'approvedSymbol': 'GABRD', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit delta', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_959522', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000187730', 'approvedSymbol': 'GABRD', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit delta', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_959549', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163285', 'approvedSymbol': 'GABRG1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_959576', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163285', 'approvedSymbol': 'GABRG1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_959603', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163285', 'approvedSymbol': 'GABRG1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}, {'UUID': 'DrugTargetsIndication121923_text_959630', 'drugName': 'Lorazepam', 'tradeNames_list': "['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensolLorazepam preservative free', 'Loreev xr', 'Temesta']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163285', 'approvedSymbol': 'GABRG1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anxiety Disorders', 'efo_term': 'anxiety disorder'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1062 | Q16 | What Small molecule therapies have been approved by the FDA to treat familial multiple nevi flammei? | There are no drug Small molecule therapies approved to treat familial multiple nevi flammei. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "familial multiple nevi flammei" OR LOWER(mesh_heading) = "familial multiple nevi flammei") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.455 | Q16 | What Small molecule therapies have been approved by the FDA to treat Genital neoplasm, female? | There are no drug Small molecule therapies approved to treat Genital neoplasm, female. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "genital neoplasm, female" OR LOWER(mesh_heading) = "genital neoplasm, female") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.494 | Q16 | What Small molecule therapies have been approved by the FDA to treat Huntington disease? | Dutetrabenazine is the only Small molecule therapy approved by the FDA to treat Huntington disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "huntington disease" OR LOWER(mesh_heading) = "huntington disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_938587', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938593', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938599', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938605', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938611', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938617', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938623', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938629', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938635', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938641', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938647', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938653', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938659', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938665', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938671', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938677', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938683', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938689', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938695', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938701', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938707', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938713', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938719', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938725', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938731', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938737', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938743', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938749', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938755', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938761', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938767', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938773', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938779', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938785', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938791', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938797', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938803', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938809', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938815', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938821', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938827', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938833', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938839', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938845', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938851', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938857', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938863', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938869', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938875', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938881', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938887', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938893', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938899', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938905', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938911', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938917', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}, {'UUID': 'DrugTargetsIndication121923_text_938923', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1299 | Q16 | What Small molecule therapies have been approved by the FDA to treat medulloblastoma? | There are no drug Small molecule therapies approved to treat medulloblastoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "medulloblastoma" OR LOWER(mesh_heading) = "medulloblastoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.289 | Q16 | What Protein therapies have been approved by the FDA to treat septic shock? | Angiotensin Ii Acetate is the only Protein therapy approved by the FDA to treat septic shock. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "septic shock" OR LOWER(mesh_heading) = "septic shock") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1072623', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072624', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072625', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072626', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072627', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072628', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072629', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072630', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072631', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072632', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072633', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072634', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072635', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072636', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072637', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072638', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072639', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072640', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072641', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072642', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072643', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072644', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072645', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072646', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072647', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072648', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072649', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072650', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072651', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072652', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072653', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072654', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072655', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072656', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072657', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072658', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072659', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072660', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072661', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072662', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072663', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}, {'UUID': 'DrugTargetsIndication121923_text_1072664', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.726 | Q16 | What Small molecule therapies have been approved by the FDA to treat aging? | There are no drug Small molecule therapies approved to treat aging. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "aging" OR LOWER(mesh_heading) = "aging") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1749 | Q16 | What Small molecule therapies have been approved by the FDA to treat ventricular fibrillation? | Amiodarone Hydrochloride is the only Small molecule therapy approved by the FDA to treat ventricular fibrillation. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "ventricular fibrillation" OR LOWER(mesh_heading) = "ventricular fibrillation") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_969559', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_969566', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_969573', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_969580', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_969587', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_969594', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1199 | Q16 | What Small molecule therapies have been approved by the FDA to treat insomnia? | There are 6 Small molecule therapy drugs that are approved to treat insomnia which are as follows: Doxepin Hydrochloride, Zolpidem Tartrate, Quazepam, Lemborexant, Daridorexant Hydrochloride, and Suvorexant. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "insomnia" OR LOWER(mesh_heading) = "insomnia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_440777', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440785', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440793', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440801', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440809', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440817', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440825', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440833', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440841', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440849', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440857', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440865', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440873', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440881', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440889', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440897', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440905', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440913', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440921', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440929', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440937', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440945', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440953', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440961', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440969', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440977', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440985', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_440993', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_441001', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_441009', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958331', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958334', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958337', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958340', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958343', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958346', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958349', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958352', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958355', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958358', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958361', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958364', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958367', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958370', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958373', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958376', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958379', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958382', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958385', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958388', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958391', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958394', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958397', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958400', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958403', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958406', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958409', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958412', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958415', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958418', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958421', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958424', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958427', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958430', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958433', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958436', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958439', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958442', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_958445', 'drugName': 'Zolpidem Tartrate', 'tradeNames_list': "['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odtZolpidem tartrate', 'Zolpimist']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964734', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964735', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964736', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964737', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964738', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964739', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964740', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964741', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964742', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964743', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964744', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964745', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964746', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000268089', 'approvedSymbol': 'GABRQ', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit theta', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964747', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000268089', 'approvedSymbol': 'GABRQ', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit theta', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964748', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000011677', 'approvedSymbol': 'GABRA3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964749', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000011677', 'approvedSymbol': 'GABRA3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha3', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964750', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000094755', 'approvedSymbol': 'GABRP', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit pi', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964751', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000094755', 'approvedSymbol': 'GABRP', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit pi', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964752', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000187730', 'approvedSymbol': 'GABRD', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit delta', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964753', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000187730', 'approvedSymbol': 'GABRD', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit delta', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964754', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163285', 'approvedSymbol': 'GABRG1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964755', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163285', 'approvedSymbol': 'GABRG1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964756', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964757', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000163288', 'approvedSymbol': 'GABRB1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964758', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000102287', 'approvedSymbol': 'GABRE', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit epsilon', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964759', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000102287', 'approvedSymbol': 'GABRE', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit epsilon', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964760', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000151834', 'approvedSymbol': 'GABRA2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964761', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000151834', 'approvedSymbol': 'GABRA2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964762', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000186297', 'approvedSymbol': 'GABRA5', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha5', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964763', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000186297', 'approvedSymbol': 'GABRA5', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha5', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}, {'UUID': 'DrugTargetsIndication121923_text_964764', 'drugName': 'Quazepam', 'tradeNames_list': "['Doral']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145863', 'approvedSymbol': 'GABRA6', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha6', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.602 | Q16 | What Small molecule therapies have been approved by the FDA to treat Prolonged QT interval? | There are no drug Small molecule therapies approved to treat Prolonged QT interval. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "prolonged qt interval" OR LOWER(mesh_heading) = "prolonged qt interval") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1636 | Q16 | What Small molecule therapies have been approved by the FDA to treat smoking cessation? | There are no drug Small molecule therapies approved to treat smoking cessation. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "smoking cessation" OR LOWER(mesh_heading) = "smoking cessation") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1454 | Q16 | What Small molecule therapies have been approved by the FDA to treat pemphigus vulgaris? | There are 2 Small molecule therapy drugs that are approved to treat pemphigus vulgaris which are as follows: Prednisone and Dexamethasone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pemphigus vulgaris" OR LOWER(mesh_heading) = "pemphigus vulgaris") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217646', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_217854', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_218062', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_218270', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_218478', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_218686', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_218894', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_219102', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_219310', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_219518', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_219726', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_219934', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_220142', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_220350', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_220558', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_220766', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_226342', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_226627', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_226912', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_227197', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_227482', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_227767', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_228052', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_228337', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_228622', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_228907', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_229192', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_229477', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_229762', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_230047', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_230332', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_230617', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_230902', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_231187', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_231472', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_231757', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_232042', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}, {'UUID': 'DrugTargetsIndication121923_text_232327', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1223 | Q16 | What Small molecule therapies have been approved by the FDA to treat ischemia? | There are no drug Small molecule therapies approved to treat ischemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "ischemia" OR LOWER(mesh_heading) = "ischemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.914 | Q16 | What Small molecule therapies have been approved by the FDA to treat chronic inflammatory demyelinating polyneuropathy? | There are no drug Small molecule therapies approved to treat chronic inflammatory demyelinating polyneuropathy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chronic inflammatory demyelinating polyneuropathy" OR LOWER(mesh_heading) = "chronic inflammatory demyelinating polyneuropathy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1407 | Q16 | What Small molecule therapies have been approved by the FDA to treat oral squamous cell carcinoma? | There are no drug Small molecule therapies approved to treat oral squamous cell carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "oral squamous cell carcinoma" OR LOWER(mesh_heading) = "oral squamous cell carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.329 | Q16 | What Small molecule therapies have been approved by the FDA to treat Abnormality of the cardiovascular system? | There are no drug Small molecule therapies approved to treat Abnormality of the cardiovascular system. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "abnormality of the cardiovascular system" OR LOWER(mesh_heading) = "abnormality of the cardiovascular system") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1442 | Q16 | What Small molecule therapies have been approved by the FDA to treat pancreatitis? | There are no drug Small molecule therapies approved to treat pancreatitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pancreatitis" OR LOWER(mesh_heading) = "pancreatitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1503 | Q16 | What Small molecule therapies have been approved by the FDA to treat post-traumatic stress disorder? | There are no drug Small molecule therapies approved to treat post-traumatic stress disorder. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "post-traumatic stress disorder" OR LOWER(mesh_heading) = "post-traumatic stress disorder") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1238 | Q16 | What Small molecule therapies have been approved by the FDA to treat large cell lung carcinoma? | There are no drug Small molecule therapies approved to treat large cell lung carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "large cell lung carcinoma" OR LOWER(mesh_heading) = "large cell lung carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.733 | Q16 | What Small molecule therapies have been approved by the FDA to treat alcohol-related disorders? | There are no drug Small molecule therapies approved to treat alcohol-related disorders. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "alcohol-related disorders" OR LOWER(mesh_heading) = "alcohol-related disorders") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.